Area of research
Molecular Biology · Oncology
Research interest
Research interests include Amyloidosis: Diagnosis, Treatment, Outcomes, Cancer Diagnosis and Treatment, Acute Myeloid Leukemia Research, and Cancer Genomics and Diagnostics.
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Etiology of TP53 mutated complex karyotype acute myeloid leukemia
Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary
200P Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study
Cancer of unknown primary (CUP) – lokal begrenzt, oligometastatisch und im Kopf-Hals-Bereich
CUP-Syndrom – die neue ESMO-Leitlinie
Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum
174P Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary
Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice
738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field
Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary
1804P Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary
Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)
519P Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study
Cryostorage to What End? – Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients
Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial
Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia